Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

Intel co-founder, wife donate $50 million for children’s hospital at Stanford

Gordon and Betty Moore donated $50 million to the Lucille Packard Children’s Hospital Stanford in Palo Alto, California, the largest private gift the hospital received since David and Lucille Packard’s donation to found the hospital.

Boston Scientific acquires privately held TAVR company for $435 million

Boston Scientific agreed to acquire Symetis SA on March 30 for $435 million in an all-cash deal.

Could spinach be used to replicate human heart tissue?

Researchers at Massachusetts’s Worcester Polytechnic Institute have found a way to convert spinach leaves into human heart tissue that can beat, according to a new Chicago Tribune article.

ACC.17: Subclinical leaflet thrombosis occurs more often in TAVR versus SAVR patients

Subclinical leaflet thrombosis occurred in 13.6 percent of patients undergoing transcatheter aortic valve replacement (TAVR) and 3.8 percent of patients undergoing surgical aortic valve replacement (SAVR), according to an analysis of two registries.

Thumbnail

FDA approves the CoreValve Evolut PRO TAVR valve for high or extreme risk patients

The FDA approved the CoreValve Evolut PRO valve for transcatheter aortic valve replacement (TAVR) in patients with severe, symptomatic aortic stenosis who are at high or extreme risk for open heart surgery.

Late-Breaking Data on Abbott's MitraClip® System Show Continued Benefit for People with Mitral Regurgitation, Most Common Heart Valve Disease

80.0% OF THOSE TREATED FREE FROM REPEAT HEART FAILURE RE-HOSPITALIZATION

ACC.17: SURTAVI trial finds TAVR, SAVR have similar all-cause mortality rates at 24 months

After two years, intermediate-risk patients with severe symptomatic aortic stenosis had similar rates of all-cause mortality or disabling stroke whether they underwent transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR), according to a randomized trial.

FDA expands approval of the Melody transcatheter pulmonary valve

The FDA approved the Melody transcatheter pulmonary valve for patients whose surgical bioprosthetic pulmonary heart valves failed.

Displaying 1009 - 1016 of 2332

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.